Mesothelioma Research News

Click the links below to view the Mesothelioma Lung Cancer Asbestos news article of your choice.


Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient

Wed, 14 Jul 2021 11:04:22 EDT

A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

AI used in battle against asbestos-linked cancer

Fri, 26 Mar 2021 08:52:30 EDT

International genomics research has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.

Tiny golden bullets could help tackle asbestos-related cancers

Mon, 26 Oct 2020 11:42:20 EDT

Gold nanotubes - tiny hollow cylinders one thousandth the width of a human hair - could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers.

Novel treatment for mesothelioma shows promise for patients

Mon, 15 Jun 2020 09:27:33 EDT

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to new research. Transarterial chemoperfusion treatment for malignant pleural mesothelioma (MPM) comes with minimal side effects and shows promise for extending the lives of patients who have limited or no remaining treatment options.

Chemotherapy/immunotherapy combo shows promise for first-line treatment of mesothelioma

Thu, 11 Jun 2020 15:24:57 EDT

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy

Mon, 30 Sep 2019 08:22:53 EDT

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. New data highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response.

Radiotherapy doubles survival for patients with mesothelioma

Mon, 29 Apr 2019 12:54:37 EDT

Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk.

Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors

Sun, 31 Mar 2019 19:25:35 EDT

A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to new results.

Combination immunotherapy improves survival in mouse models of mesothelioma

Mon, 02 Apr 2018 14:24:58 EDT

Investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.

Subset of carbon nanotubes poses cancer risk similar to asbestos in mice

Mon, 06 Nov 2017 13:20:18 EST

Researchers have shown for the first time in mice that long and thin nanomaterials called carbon nanotubes may have the same carcinogenic effect as asbestos: they can induce the formation of mesothelioma. The findings were observed in 10 percent -- 25 percent of the 32 animals included in the study, which has not yet been replicated in humans.

Go to main Mesothelioma cancer resource page...